LB-100 is a medication being studied for its potential to inhibit a specific enzyme called PP2A. This enzyme is involved in various cellular processes, and by inhibiting it, LB-100 may help to enhance the effectiveness of other cancer treatments. In this trial, LB-100 is being tested in combination with another medication to see if it can improve outcomes for patients with metastatic colorectal cancer.

Atezolizumab is an immunotherapy drug that works by blocking a protein called PD-L1. This protein can prevent the immune system from attacking cancer cells. By inhibiting PD-L1, Atezolizumab helps the immune system recognize and destroy cancer cells more effectively. It is being used in this trial to treat patients with metastatic colorectal cancer, in combination with LB-100, to evaluate if the combination is more effective than standard treatments.

Microsatellite Stable Colorectal Cancer – This type of colorectal cancer is characterized by the absence of microsatellite instability, meaning the DNA repair system is functioning normally. It typically progresses through the accumulation of genetic mutations that lead to uncontrolled cell growth in the colon or rectum. Patients with this condition often experience symptoms such as changes in bowel habits, blood in the stool, and abdominal discomfort. The disease can spread to other parts of the body, known as metastasis, which complicates its progression. Unlike microsatellite instability-high colorectal cancer, this type does not respond well to certain immunotherapies. The progression of the disease is monitored through various clinical parameters to assess its impact on the patient’s health.